Serum carbohydrate antigen (CA) 19-9 as a prognostic factor in cholangiocarcinoma: A meta-analysis
Tóm tắt
This study was performed to determine the prognostic role of preoperative serum carbohydrate antigen (CA) 19-9 levels in the survival of patients with cholangiocarcinoma. Articles published up to June 1st, 2010 that evaluated preoperative CA19-9 levels and the prognosis of cholangiocarcinoma were collected for meta-analysis. The required information for calculating individual relative risk (RR) was extracted from the studies, and a combined overall RR was estimated. Nine eligible studies were included. One study dealt with extra-hepatic cholangiocarcinoma, while the other eight studies analyzed intra-hepatic cholangiocarcinoma. The mean methodological quality score was 74.1%, ranging from 65.5% to 82.5%. The overall RR for the nine studies was 1.28 (95% confidence interval = 1.10–1.46), and the Z-score for overall effect was 13.83 (P<0.001). The association between serum CA19-9 level and lymph node involvement was also assessed. The combined RR was 1.471 (95% confidence interval = 0.411–5.264) and Z-score for overall effect was 0.59 (P = 0.553). CA19-9 levels were associated significantly with the prognosis of patients with cholangiocarcinoma. This meta-analysis shows that elevation of preoperative CA19-9 levels is correlated with a poor prognosis of patients with cholangiocarcinoma. However, larger scale and randomized studies are needed to draw a more substantive conclusion.
Tài liệu tham khảo
Blechacz B, Gores G J. Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. Hepatology, 2008, 48(1): 308–321
Welzel TM, McGlynn K A, Hsing AW, O’Brien T R, Pfeiffer RM. Impact of classification of hilar cholangiocarcinomas (Klatskin tumors) on the incidence of intra- and extrahepatic cholangiocarcinoma in the United States. J Natl Cancer Inst, 2006, 98(12): 873–875
Forsmo HM, Horn A, Viste A, Hoem D, èvrebø K. Survival and an overview of decision-making in patients with cholangiocarcinoma. Hepatobiliary Pancreat Dis Int, 2008, 7(4): 412–417
Heimbach J K, Haddock M G, Alberts S R, Nyberg S L, Ishitani M B, Rosen C B, Gores G J. Transplantation for hilar cholangiocarcinoma. Liver Transpl, 2004, 10(10 Suppl 2): S65–S68
Heimbach J K, Gores G J, Haddock M G, Alberts S R, Nyberg S L, Ishitani M B, Rosen C B. Liver transplantation for unresectable perihilar cholangiocarcinoma. Semin Liver Dis, 2004, 24(2): 201–207
Uenishi T, Hirohashi K, Kubo S, Yamamoto T, Yamazaki O, Kinoshita H. Clinicopathological factors predicting outcome after resection of mass-forming intrahepatic cholangiocarcinoma. Br J Surg, 2001, 88(7): 969–974
DeOliveira M L, Cunningham S C, Cameron J L, Kamangar F, Winter J M, Lillemoe K D, Choti M A, Yeo C J, Schulick R D. Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Ann Surg, 2007, 245(5): 755–762
Su C H, Tsay S H, Wu C C, Shyr YM, King K L, Lee C H, Lui WY, Liu T J, P’eng F K. Factors influencing postoperative morbidity, mortality, and survival after resection for hilar cholangiocarcinoma. Ann Surg, 1996, 223(4): 384–394
Stroup D F, Berlin J A, Morton S C, Olkin I, Williamson G D, Rennie D, Moher D, Becker B J, Sipe T A, Thacker S B. Metaanalysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA, 2000, 283(15): 2008–2012
Yusuf S, Peto R, Lewis J A, Collins R, Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis, 1985, 27(5): 335–371
Miwa S, Miyagawa S, Soeda J, Kawasaki S. Matrix metalloproteinase-7 expression and biologic aggressiveness of cholangiocellular carcinoma. Cancer, 2002, 94(2): 428–434
Chantajitr S, Wilasrusmee C, Lertsitichai P, Phromsopha N. Combined hepatocellular and cholangiocarcinoma: clinical features and prognostic study in a Thai population. J Hepatobiliary Pancreat Surg, 2006, 13(6): 537–542
Yi B, Zhang B H, Zhang Y J, Jiang X Q, Zhang B H, Yu W L, Chen Q B, Wu M C. Surgical procedure and prognosis of hilar cholangiocarcinoma. Hepatobiliary Pancreat Dis Int, 2004, 3(3): 453–457
Huang J L, Biehl T R, Lee F T, Zimmer PW, Ryan J A Jr. Outcomes after resection of cholangiocellular carcinoma. Am J Surg, 2004, 187(5): 612–617
Fernández-Ruiz M, Guerra-Vales J M, Colina-Ruizdelgado F. Comorbidity negatively influences prognosis in patients with extrahepatic cholangiocarcinoma. World J Gastroenterol, 2009, 15(42): 5279–5286
Abdel Wahab M, Fathy O, Elghwalby N, Sultan A, Elebidy E, Abdalla T, Elshobary M, Mostafa M, Foad A, Kandeel T, Abdel Raouf A, Salah T, Abu Zeid M, Abu Elenein A, Gad Elhak N, ElFiky A, Ezzat F. Resectability and prognostic factors after resection of hilar cholangiocarcinoma. Hepatogastroenterology, 2006, 53(67): 5–10
Kim H J, Yun S S, Jung K H, Kwun W H, Choi J H. Intrahepatic cholangiocarcinoma in Korea. J Hepatobiliary Pancreat Surg, 1999, 6(2): 142–148
Ohtsuka M, Ito H, Kimura F, Shimizu H, Togawa A, Yoshidome H, Miyazaki M. Results of surgical treatment for intrahepatic cholangiocarcinoma and clinicopathological factors influencing survival. Br J Surg, 2002, 89(12): 1525–1531
Miwa S, Miyagawa S, Kobayashi A, Akahane Y, Nakata T, Mihara M, Kusama K, Soeda J, Ogawa S. Predictive factors for intrahepatic cholangiocarcinoma recurrence in the liver following surgery. J Gastroenterol, 2006, 41(9): 893–900
Uenishi T, Yamazaki O, Tanaka H, Takemura S, Yamamoto T, Tanaka S, Nishiguchi S, Kubo S. Serum cytokeratin 19 fragment (CYFRA21-1) as a prognostic factor in intrahepatic cholangiocarcinoma. Ann Surg Oncol, 2008, 15(2): 583–589
Zhou L, He X D, Cui Q C, Zhou WX, Qu Q, Zhou R L, Rui J A, Yu J C. Expression of LAPTM4B-35: a novel marker of progression, invasiveness and poor prognosis of extrahepatic cholangiocarcinoma. Cancer Lett, 2008, 264(2): 209–217
Shen W F, Zhong W, Xu F, Kan T, Geng L, Xie F, Sui C J, Yang J M. Clinicopathological and prognostic analysis of 429 patients with intrahepatic cholangiocarcinoma. World J Gastroenterol, 2009, 15(47): 5976–5982
Jiang W, Zeng Z C, Tang Z Y, Fan J, Zhou J, Zeng M S, Zhang J Y, Chen Y X, Tan Y S. Benefit of radiotherapy for 90 patients with resected intrahepatic cholangiocarcinoma and concurrent lymph node metastases. J Cancer Res Clin Oncol, 2010, 136(9): 1323–1331
Cho S Y, Park S J, Kim S H, Han S S, Kim Y K, Lee KW, Lee S A, Hong E K, Lee W J, Woo S M. Survival analysis of intrahepatic cholangiocarcinoma after resection. Ann Surg Oncol, 2010, 17(7): 1823–1830
Saxena A, Chua T C, Sarkar A, Chu F, Morris D L. Clinicopathologic and treatment-related factors influencing recurrence and survival after hepatic resection of intrahepatic cholangiocarcinoma: a 19-year experience from an established Australian hepatobiliary unit. J Gastrointest Surg, 2010, 14(7): 1128–1138
Kannagi R. Carbohydrate antigen sialyl Lewis a—its pathophysiological significance and induction mechanism in cancer progression. Chang Gung Med J, 2007, 30(3): 189–209
Takada A, Ohmori K, Yoneda T, Tsuyuoka K, Hasegawa A, Kiso M, Kannagi R. Contribution of carbohydrate antigens sialyl Lewis A and sialyl Lewis X to adhesion of human cancer cells to vascular endothelium. Cancer Res, 1993, 53(2): 354–361
Briggs C D, Neal C P, Mann C D, Steward W P, Manson M M, Berry D P. Prognostic molecular markers in cholangiocarcinoma: a systematic review. Eur J Cancer, 2009, 45(1): 33–47
Berghmans T, Paesmans M, Mascaux C, Martin B, Meert A P, Haller A, Lafitte J J, Sculier J P. Thyroid transcription factor 1—a new prognostic factor in lung cancer: a meta-analysis. Ann Oncol, 2006, 17(11): 1673–1676
Schoenleber S J, Kurtz DM, Talwalkar J A, Roberts L R, Gores G J. Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: systematic review and meta-analysis. Br J Cancer, 2009, 100(9): 1385–1392